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INTRODUCTION 
Upper gastrointestinal endoscopy is routinely performed everyday for 
a number of patients in the department of Medical Gastroenterology, 
Government Rajaji Hospital. It is generally considered the diagnostic 
method of choice in uninvestigated dyspepsia because it allows 
identification of structural causes of dyspepsia and most importantly 
excludes carcinoma, but examination of all patients is hard to perform. The 
reason is the high annual incidence of dyspepsia. The issue is even more 
important in developing countries like ours with limited access to diagnostic 
services. There is no generally accepted consensus about the age cut off for 
upper GI endoscopy, because it mainly depends on the regional age-specific 
incidence of gastric cancer. 
The association of Helicobacter pylori with various gastrointestinal 
disorders has been studied in the past few years. The relation between peptic 
ulcer and H.pylori is well established throughout world literature. The ultra 
rapid urease test has been used in the past few years to study the presence of 
organism in the endoscopic specimen. Though there are several methods 
used to detect the organism, most of them are expensive and cumbersome to 
perform. This test provides a quicker and cheaper means to study the 
organism with a high degree of sensitivity and specificity. 
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The association of H.pylori with peptic ulcer and gastric 
adenocarcinoma was suggested by its discoverer Barry Marshall. In 1984, it 
was again described shortly after subsequent studies assessed its role in 
GERD and non ulcer dyspepsia. It was found to be one of the etiological 
factors for gastric adenocarcinoma and gastric MALTomas in 1991. It was 
identified as a grade I carcinogen in 1994 and the importance of its 
eradication in patients with a positive family history of carcinoma was 
stressed. Its association with non ulcer dyspepsia is less well understood 
despite several studies in the past. The histology of non ulcer dyspepsia has 
also not been studied in detail in the past. The few studies which are 
available indicate that there could be a role for H.pylori but has not been 
determined with accuracy. 
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REVIEW OF LITERATURE 
DYSPEPSIA 
Dyspepsia refers to chronic or recurrent pain or discomfort centered in 
the upper abdomen. The term dyspepsia originates from the Greek words 
dys and pepsin which means poor and digestion respectively.1, 2 It has been 
used rather loosely including symptoms of vague upper abdominal or 
periumbilical discomfort or pain, early satiety, abdominal bloating, nausea 
with or without vomiting and belching. The possibility of serious organic 
disease should be considered when alarm symptoms or signs are present 
which include the following -  
1. Age older than 55 years with new-onset dyspepsia 
2. Family history of upper gastrointestinal cancer 
3. Unintended weight loss 
4. Gastrointestinal bleeding 
5. Progressive dysphagia 
6. Odynophagia 
7. Unexplained iron-deficiency anemia 
8. Persistent vomiting 
9. Palpable mass or lymphadenopathy 
10. Jaundice3 
 4
Diseases presenting with dyspepsia fall into two general categories: 
organic and functional. Overall, most patients with dyspepsia have no 
underlying identifiable disease process. The commonest organic causes of 
dyspepsia are peptic ulcer disease, gastroesophageal reflux, biliary tract 
disease, and gastric cancer.2 Dyspeptic symptoms may be present in both 
organic and functional gastrointestinal disorders. Certain symptoms and 
physical signs as mentioned before may help to differentiate these organic 
causes from functional dyspepsia. 
The ROME III criteria for functional dyspepsia are as follows - 
One or more of: 
Bothersome post prandial fullness 
Early satiety 
Epigastric pain  
Epigastric burning 
AND 
No evidence of structural disease (even after performing endoscopy) that is 
likely to explain the symptoms. 
The above criteria must be fulfilled for the past three months with symptom 
onset at least six months before diagnosis. 1,4 
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Based on the different symptom complex present in the majority of 
the non ulcer dyspepsia sufferers the patients are classified into the 
following groups after confirming the diagnosis by endoscopy for easier 
means of selection of medical therapy- 
1. Ulcer-like: predominant symptom is pain centered on the upper abdomen 
2. Dysmotility-like: predominant symptom is an unpleasant or troublesome 
nonpainful sensation or discomfort centered in the upper abdomen and may 
be characterized by or associated with upper abdominal fullness, early 
satiety, bloating or nausea. 
3.  Reflux-like dyspepsia, 
4. Essential (non-specific) subgroups. These were proposed by the 
International working party in 1988.1,5,6 
The presence of retrosternal burning pain or heartburn reliably 
indicates GERD as per various studies and dysphagia almost always 
indicates organic esophageal pathology. 
 
 
 
 
 
 6
TABLE 1 DIFFERENTIAL DIAGNOSIS OF DYSPEPSIA1 
Peptic ulcer disease 7-25% 
GERD 2-29% 
Gastric or esophageal cancer 1-3% 
Biliary disease <5% 
Pancreatic disorders <5% 
Metabolic disorders <5% 
Celiac disease Rare 
Functional dyspepsia 50-60% 
 
Functional dyspepsia may represent up to 60% of all patients with 
dyspeptic symptoms. In the majority of patients with a negative conventional 
evaluation, specialized studies such as esophageal pH monitoring, 
esophageal manometry, lactose tolerance testing, antroduodenal motility 
study and radioscintigraphy may identify an underlying organic cause for the 
symptoms but are not routinely indicated for all patients as initial evaluation 
techniques. Various studies have been done in the past to determine the cut 
off age above which endoscopy should be performed as the initial diagnostic 
technique. No specific age has been determined to date. Missing early (and 
hence curable) gastric cancer is often of greatest concern to the clinician 
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contemplating empirical therapy, especially in an older patient. Fear of 
gastric cancer has to be taken into account when planning the management 
of dyspepsia. It is generally accepted that the incidence of serious lesions 
like gastric malignancy is low below the age of 50 years and endoscopy may 
not be essential in these patients without alarm symptoms. The yield from 
endoscopy in patients being investigated for dyspepsia increases with 
advancing age but is generally low. 
A potential benefit of endoscopy is that gastric ulcers can be 
confirmed to be benign by performing biopsy.7 Endoscopy permits gastric 
biopsy specimens to be taken to diagnose H. pylori status; rapid urease 
testing is relatively inexpensive and is sensitive (95%) and specific (up to 
100%). However, a single biopsy may miss 5–10% of cases, and recent 
antibiotic use or antisecretory therapy will increase the false-negative rate. 
Moreover, there is limited and unconvincing evidence that endoscopy leads 
to improvement in the patient’s satisfaction scores in dyspepsia. Cost 
effectiveness is the other consideration. Amongst the various causes of 
dyspepsia, functional dyspepsia rates highest and it may not be cost effective 
to choose endoscopy as the first investigation. Various studies have proved a 
good correlation between alarm symptoms and the presence of serious 
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organic disease and thus a good symptom analysis can be used to pick up 
organic disease at an earlier date.8, 9  
Review of past literature reveals that endoscopy may not be needed in 
younger patients without alarm symptoms.10 
Gillen et al found in their study that upper GI malignancy is extremely 
rare in patients <55 years presenting with uncomplicated dyspepsia and, 
when found, is usually incurable. Consequently, concern about missing 
underlying curable malignancy is not a valid indication for endoscopying 
patients <55 years presenting with uncomplicated dyspepsia. 11 
Marmo et al concluded that the age threshold for endoscopy should be 
lowered in males to decrease the risk of missing cancers, and can be safely 
increased in females without affecting outcomes. In patients with 
uncomplicated dyspepsia, the combination of age and gender provides a 
better discriminant power than age alone. 12  
Williams et al have found in their study that young patients with 
simple dyspepsia are over investigated. A majority can be treated safely with 
antacids and/or histamine receptor type 2 antagonists. 13   
Christie et al concluded that gastric cancer is rare below the age of 55 
(7.8% of all cases) and, even in the presence of established open access 
endoscopy, presents with suspicious symptoms or signs in 96% of cases. 
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The age limit for screening uncomplicated dyspepsia can be raised safely to 
55 years. 14 
HELICOBACTER PYLORI 
After its discovery by Warren and Marshall in the year 1982 and its 
association with gastritis, it has been extensively studied in the pathogenesis 
of various gastric lesions. It is a spiral gram negative bacterium which is 
motile and mainly colonizes the zone beneath the gastric mucus which 
overlies the gastric epithelial cells. The organism may be found in any part 
of the stomach but prefers the antrum where there parietal cells are scanty in 
number or absent. H.pylori can be demonstrated in saliva, gastric juice and 
dental plaques by the sensitive PCR technique. Oro oral and feco-oral are 
likely pathways of transmission.  
The infection is more prevalent in the developing countries (up to 
90%) and is facilitated by conditions of overcrowding, poor living facilities. 
Low socioeconomic status and low education level are also known to 
increase infection rates.1,2 Rate of acquisition of infection increase with age 
and there is no specific gender predilection. There are high infection rates 
among smokers.15 
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PATHOGENESIS OF GASTRIC LESIONS 
Cag A gene possessing strains are common in people with peptic ulcer 
or adenocarcinoma. All HP strains possess Vac A gene but only 40% are 
toxigenic. The characteristic motility of the organism allows it to move 
rapidly through viscous mucus. Once the organism is safely encased in the 
mucus, it is able to fight the gastric acidity with the help of urease and 
converts urea (of which there is abundance from saliva and gastric juices) 
into ammonia, which is a strong base, thus creating a cloud of acid 
neutralizing chemicals around the organism and protecting it from gastric 
acidity. 1, 2, 16, 17, 18 
 Another defense that the organism has is that the body’s natural 
defenses cannot reach the bacterium in the mucus lining of the stomach. The 
immune system responds strongly to the infection with a host of immune 
cells which unfortunately cannot get through the gastric lining. But they are 
localized just outside the stomach lining and thus a vicious cytotoxic 
immune response ensues, producing gastritis and peptic ulceration. It may 
not be the organism itself which causes peptic ulcer but in fact the host 
response to H.pylori.  
Although the organism is non invasive, the bacterium stimulates 
chronic gastritis by provoking a local imflammatory response in the 
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underlying epithelium due to a variety of cytotoxins. Once infection in the 
antrum is established, there is depletion of antral somatostatin and 
stimulation of gastrin release from G cells. Subsequent hypergastrinemia 
stimulates acid production by the parietal cells, leading to duodenal 
ulceration. The role of HP in gastric ulcer is less clear but HP probably 
reduces gastric mucosal resistance to attack from acid and pepsin .1 
Host response to infection is characterized by an acute neutrophilic 
infiltrate in the acute stage followed by a chronic inflammatory cell infiltrate 
in the later stages, the Th1 response predominating.  
The following types of chronic gastritis have been found to be 
associated with HP infection - 
Type A: atrophic in nature and have parietal cell antibodies 
Type B: no parietal cell antibodies 
Type AB: atrophic and patchy 
Chronic gastritis in HP has been found to be associated with intestinal 
metaplasia and increases risk of gastric adenocarcinoma. HP infection has 
been very strongly linked to duodenal ulcer, the prevalence rates reaching 
close to 100%. Eradication of HP in DU gives awarding results. The most 
serious lesion caused by HP is gastric cancer. The pathogenesis is 
represented as follows by Correa’s multi step hypothesis.19 
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H.pylori  Chronic active gastritis  Atrophy  
     Dysplasia  Intestinal metaplasia  
 
    Distal gastric cancer 
TABLE 2 Association of HP with various gastric disorders1 
Chronic gastritis 50-65% 
Duodenal ulcer 95-98% 
Gastric ulcer 60-75% 
Non ulcer dyspepsia 50-60% 
Gastric adenocarcinoma six fold increase 
Gastric MALToma 93-98% 
 
DIAGNOSIS OF INFECTION 
The presence of H.pylori in the stomach can be detected by several invasive 
and non invasive methods.  
Invasive Non invasive 
Culture 
Histology of biopsied specimen 
Rapid urease test 
Serology 
Urea breath test 
Stool antigen test, PCR, urine antigen 
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The choice of the test used depends upon the accuracy, cost, 
availability and whether the patient will be undergoing endoscopy.2, 3, 20 
Stool antigen tests are increasingly being used as simple non invasive 
methods for H.pylori diagnosis. Serology is useful as a screening test but 
cannot differentiate between current and past infection. 
TABLE 3 COMPARISONS OF VARIOUS METHODS OF DETECTION 
OF HP 21 
Feature Histo Culture RUT ELISA UBT SAT PCR 
Sensitivity (%) 90 86 88-92 90-100 95-100 91 93-96 
Specificity (%) 88 100 92-100 91-100 95-100 93 100 
Invasive + + + - - - - 
Expensive + + - - - - + 
Results within 
24 hrs 
- - + - + + + 
Can confirm 
eradication 
- - - - + - + 
Accuracy 
affected by 
recent treatment 
with 
PPI/antibiotics 
+ + + - + - - 
Histo-histology, +=yes, -=no, PCR=polymerase chain reaction, RUT=rapid urease test, 
UBT= urea breath test, SAT= stool antigen test, ELISA= enzyme linked 
immunosorbent assay 
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MANAGEMENT OF DYSPEPSIA AND H.PYLORI INFECTION 
The clinician evaluating a patient with dyspeptic symptoms should 
recognize the limitations of history taking and physical examination in this 
setting. The principal utility of the clinical history and physical examination 
is to-  
(1)   Identify patients with GERD and NSAID-induced dyspepsia  
(2) Identify patients with alarm symptoms who may require early 
investigation. 
Patients who have typical symptoms of reflux disease should be 
managed as having GERD. Patients whose symptoms are predominantly 
related to bowel function may have IBS and should be treated appropriately. 
Alarm features are used to try and identify patients who need early 
investigation with endoscopy. The negative predictive value was always 
>97% in various trials, reflecting the fact that upper gastrointestinal 
malignancy was a rare diagnosis. 
There are 5 initial approaches to the management of dyspepsia: 
 (1) Empirical acid suppression;  
(2) A non-invasive test for H pylori, with a urea breath test, stool antigen 
test, or serology, and reserving endoscopy for positive cases; 
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 (3) A noninvasive test for H pylori and eradication therapy for positive 
cases;  
(4) Empirical H pylori eradication therapy without testing;  
(5) Early endoscopy.3 
PATIENTS WITH DYSPEPSIA AND ALARM SYMPTOMS 
Due to the small but clear-cut increase in the risk of upper 
gastrointestinal malignancy, new-onset alarm symptoms or new onset of 
symptoms after the age of 55 years should prompt early endoscopy. This 
cutoff was chosen because the risk of malignancy in most populations is <10 
per 100,000 below the age of 55 years. The probability of detecting an early 
gastric cancer is therefore very low below this age.3  
PATIENTS WITH DYSPEPSIA AND NO ALARM SYMPTOMS 
The optimal management strategy for the patient who presents with 
new-onset dyspepsia and no alarm features has been dominated by testing 
for H pylori and treating all positive cases empirically with antibacterial 
therapy. However, there are other choices, including no testing but empirical 
medical therapy (e.g., an antisecretory agent) with any subsequent 
investigation reserved for failures or immediate evaluation by upper 
endoscopy in all cases and targeting therapy based on the results.3 
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In primary care, empirical antisecretory therapy remains popular. 
Only a minority of patients with dyspepsia has peptic ulcers, and even fewer 
have cancer. Therefore, in 1985, the American College of Physicians 
recommended, based on a literature review of outcomes and cost, that 
antisecretory medical therapy is preferable for patients without obvious 
organic disease who are younger than 45 years of age. The American 
College of Physicians further suggested that endoscopy (rather than a barium 
series) should be reserved for patients who have little or no response to 
therapy after 7–10 days or for patients whose symptoms have not resolved 
after 6–8 weeks. However, whether this age threshold is still applicable and 
the utility of empirical therapy now continue to be debated, especially in 
terms of continuing such treatment on a long-term basis in those with 
undiagnosed H pylori infection. 
The 3 strategies that have undergone intense evaluation are empirical 
acid suppression, H pylori test and treat, and early endoscopy. Preliminary 
data suggest that H pylori test and treat is more cost-effective than empirical 
PPI therapy in patients with dyspepsia. As a strategy, the efficacy of H 
pylori test and treat will vary according to whether the test is performed in 
primary or secondary care and the prevalence of infection in the population. 
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“Cure” is to be offered to the patients who are infected and an alternate 
approach for those who test negative.  
THE MANAGEMENT OF DOCUMENTED NON 
ULCER/FUNCTIONAL DYSPEPSIA 
1. Initial PPI therapy 
2. Acid suppression, 
3. Prokinetic therapy,  
4. H pylori eradication therapy, and 
5.  Psychological therapies.22  
Overall, the only therapies that have established efficacy in functional 
dyspepsia are H pylori eradication and PPI therapy. H pylori eradication is 
the most cost-effective approach in patients who are positive because this 
treatment is only given once for a long-term effect. In H pylori–negative 
patients with functional dyspepsia and those who fail to respond to 
eradication therapy, a one month course of PPI therapy may be warranted. 
The association between H.pylori and the non ulcer dyspepsia has 
been analyzed for many years and various studies have tried to prove the 
association so that these patients can be subjected to eradication therapy. But 
definite evidence is lacking. A study performed in Germany by Bajorsky et 
al concluded that HP-infection per se contributes to dyspepsia. 85% HP-
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positive dyspeptic patients improved after HP-eradication, when other 
potential organic causes for dyspepsia had been ruled out. However, many 
patients did not completely recover but the symptoms only partly decreased 
which parallels the persistence of part of the inflammatory infiltration in the 
gastric mucosa. This emphasizes the importance of HP-gastritis as an 
organic disease causing dyspeptic symptoms. 23 
The first national workshop on H.pylori was held in Mumbai in the 
year 1997 and the significant conclusions were as follows- 
1. The prevalence of H.pylori infection in healthy or asymptomatic persons 
in India varied from 31-84 %. 
2. Prevalence mainly depends on the age, socioeconomic status, housing, 
sanitation and methods used for diagnosis.  
3. Age related prevalence studies show that in India, infection occurs at an 
earlier age than in the west. 
4. The frequency of H.pylori in non ulcer dyspepsia varies from 60-85% and 
no correlation was found between the degree of gastric inflammation and 
symptoms of non ulcer dyspepsia. 
5. There is no large study on the histological picture of the gastric mucosa 
and its correlation to symptom response. 
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6. Invasive techniques have been the preferred mode of diagnosis of H.pylori 
in India; of these tests rapid urease test has been most popular, both the 
commercially available kits and the in house developed ones. 
Anitha Kamath et al compared the sensitivity and specificity of a 
commercially available urease test and an in house prepared urease test 
using histology as the gold standard. The in house urease test was cheap and 
more sensitive than the commercially available helicochek kit. 24  
Thayumanavan L et al, Madurai studied the prevalence of H.pylori in 
gastroduodenal diseases during routine upper gastrointestinal endoscopies at 
Madurai and concluded that the organism is widely prevalent in southern 
parts of Tamil Nadu, the rapid urease test is cheap, simple and useful for 
detecting the organism, and the prevalence of infection was nearly as high in 
non ulcer dyspeptics (66%) as those with DU (86%).25 
In the research setting, culture should be included in the protocol for 
confirming eradication, till the urea breath test is widely available. Serology 
is ideal for epidemiological studies.26 
Warren Marshall observation proved that greater than 90% of DU 
patients were infected compared to 40% of controls. 27 
 Four endoscopic surveys showed H.pylori infection in 43-79% of 
NUD patients. These numbers were well above control in three of these 
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surveys. At least 50% of infected persons had no symptoms. Some have 
found that infected patients are likely to have reflux like or ulcer like 
symptoms. 28, 29 
The EUROGAST study group showed a positive correlation between 
the prevalence of gastric cancer and H.pylori in different parts of the world. 
The correlation was convincing and statistically significant. 30  
 PC Jain et al studied the presence of H.pylori in patients with upper 
gastrointestinal symptoms using the rapid urease test and found significant 
prevalence of the organism in both ulcer and non ulcer dyspepsia. 31  
 There have been very few studies on the histopathological aspects of 
non ulcer dyspepsia and its relation to H.pylori. One study done in Nigeria 
found that significant mucosal lesions were found in patients who were 
infected with H.pylori despite normal endoscopy.32 Studies from India are 
lacking. 
ERADICATION OF HELICOBACTER PYLORI 
All patients suffering from gastric or duodenal ulcers who are infected 
with H.pylori should be treated with antimicrobials regardless of whether 
they are suffering from the initial presentation of the disease or from 
recurrence. Drugs known to cause dyspepsia should be discontinued 
wherever possible. However, the issue of eradicating H.pylori in non ulcer 
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dyspepsia remains controversial. Recent studies suggest that H.pylori should 
be eradicated even in non ulcer dyspepsia. 1, 47, 48 H.pylori eradication is 
defined as negative test for H.pylori at least 28 days after therapy. 
FACTORS WHICH MODIFY TREATMENT 
1. Bismuth and PPIs specifically inhibit the bacterial enzyme urease so that 
urease based tests might fail to detect residual infection or recurrence. 
2. H.pylori tends to move to the proximal stomach during suppression of 
acid secretion. So biopsy based tests become inaccurate 
3. C13 and C14 urea breath tests are most accurate because they sample the 
whole stomach and so regarded as gold standard to confirm eradication. 
4. Serology is not useful to confirm eradication as it takes at least 6 months 
for the antibody titer to fall significantly 
5. Dual therapy with a two week combination of omeprazole or ranitidine 
bismuth citrate and either amoxicillin or clarithromycin eradicated H.pylori 
in 50-80%. In triple therapy, eradication may be around 50-70%. One week, 
twice daily PPI based triple therapy eradicates in about 90%. Second line 
regimens include seven days treatment with omeprazole and thrice daily 
amoxicillin and metronidazole or a PPI based regimen. 
 
 
 22
 
TABLE 4 TRIPLE REGIMENS WITH AMOXICILLIN AND 
METRONIDAZOLE 
 REGIMEN 1 REGIMEN 2 REGIMEN 3 
Drug Omeprazole+ 
amoxicillin+ 
metronidazole 
Ranitidine+ 
amoxicillin+ 
metronidazole 
Bismuth+tetracycline/ 
amoxicillin+  
metronidazole 
Dose 
(daily) 
40mg once+ 
500mg thrice+ 
400mg thrice 
300mg once+ 
750mg thrice+ 
500mg thrice 
120mg 4 times+ 
500mg 4 times+ 
200-400mg 4 times 
Duration 7 days 12 days 2 weeks 
Efficacy 95% 90% 60-90% 
Side effects Diarrhea, nausea 
 
These standard triple regimens have been replaced by shorter 
regimens which contain amoxicillin or clarithromycin along with a proton 
pump inhibitor. These regimens are equally effective in eradicating the 
organism. 
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TABLE 5 LOW DOSE TRIPLE THERAPY2 
 REGIMEN 1 REGIMEN 2 
Drugs PPI+ Clarithromycin+ 
Metronidazole 
PPI + Amoxicillin+ 
Clarithromycin 
Dose(daily) Once/twice daily+ 
250mg twice+ 
400mg twice 
Twice + 
1 gm twice+ 
250-500 mg twice 
Duration 7 days 
Efficacy 90% 90% 
Side effects Uncommon: diarrhea, nausea with metronidazole 
 
QUADRUPLE THERAPY 
PPI (once/twice daily), colloid bismuth sub citrate(120mg four times daily), 
tetracycline(500 mg four times daily), metronidazole(400-500mg 3-4 times 
daily) 
Duration of therapy: seven days 
Efficacy: 85-95% 
Side effects: diarrhea, nausea2 
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SEQUENTIAL THERAPY 
Day 1-5 
Proton pump inhibitors twice a day 
Amoxicillin one gram twice a day 
Day 6-10 
Proton pump inhibitors twice a day 
Clarithromycin 500 mg twice a day 
Tinidazole 500 mg twice a day. 
Sequential therapy gives an eradication rate of around 98%. The 
sequential therapy gave a higher eradication rate than the conventional triple 
therapy and it has been suggested that it should be made the standard 
eradication therapy for H.pylori.33 
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AIMS AND OBJECTIVES 
The aims of the study were as follows- 
1. To study the value of upper gastrointestinal endoscopy in patients 
with new onset previously uninvestigated dyspepsia with and without 
alarm symptoms 
2. To study the prevalence of H. pylori in non ulcer dyspepsia in various 
age groups 
3. To study the histopathological aspects of non ulcer dyspepsia. 
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MATERIALS AND METHODS 
 THE STUDY GROUP 
The study was conducted on inpatients or outpatients visiting the 
Gastroenterology department and medical wards. Approval from the ethical 
committee was obtained. The study was a cross sectional study conducted 
for a period of one year between June 2007-08.  
Inclusion criteria  
1. Patients aged >18 years 
2. New onset previously uninvestigated dyspeptic symptoms for more than 
three months’ duration including- 
1. Upper abdominal pain/discomfort 
2. Early satiety/Post prandial fullness 
3. Abdominal bloating 
4. Recurrent belching 
Exclusion criteria 
1. Intake of antibiotics, metronidazole, PPI or NSAIDs at present or within 
past 15 days 
2. Acute gastrointestinal bleeding 
3. Pregnancy 
4. Severe systemic illness 
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5. Symptoms suggestive of reflux disease 
6. Gallstone disease. 
7. Patients refusing endoscopy. 
METHODS 
A total number of 282 patients were studied out of which 224 were 
included in the study as per the inclusion and exclusion criteria. They were 
also classified according to the socioeconomic status using the Modified 
Kuppuswamy classification34 which utilizes three parameters namely 
education, occupation and monthly income. Socioeconomic status score was 
assigned to each patient. Informed consent was obtained from all patients 
before the start of the study. 
A detailed history was elicited from the patient about the type and 
duration of dyspepsia. The presence or absence of alarm symptoms was also 
noted as previously mentioned. Baseline investigations were done to rule out 
major systemic illness. An ultrasonographic examination of the abdomen 
was done to rule out gallstone or mass lesion. Patients with documented gall 
stone disease were excluded from the study.  
A detailed informed consent was obtained from the patients for 
undergoing upper GI endoscopy. All patients were advised overnight fasting 
and OGD was performed on empty stomach in the morning. OGD was 
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performed with a flexible fibreoptic endoscope and the mucosa of the 
stomach and pylorus was analyzed for any lesions. Biopsies were taken from 
the fundus, body and antral mucosa for histopathology. An additional 
sample was taken from the antral mucosa for the tissue ultra rapid urease 
reaction. After sterilization, the scope and biopsy forceps were washed with 
sterile distilled water so that no error in the test occurred due to changes in 
pH. 
THE ULTRA RAPID UREASE TEST 
This test is a modification of the standard urease test so that a positive 
result is available almost immediately. The basic principle behind the test is 
that H.pylori produces large quantities of urease which rapidly hydrolyses 
urea to ammonia. The urea in the test solution is hydrolyzed to ammonia by 
the preformed urease present in the H.pylori positive antral biopsy specimen. 
The color of the solution changes from yellow to pink due to the change in 
pH of the solution. The test solution consists of 0.5ml of freshly prepared 
1% urea (W/V) in sterile distilled water to which is added two drops of 1% 
phenol red as a pH indicator in clean capped bottles. 
PROCEDURE AND RESULTS 
A single antral mucosal biopsy was taken within five centimeters of 
the pylorus and the specimen was placed immediately within the test 
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solution and remained undisturbed. H.pylori positive specimens changed the 
color of the solution from yellow to pink and the results were read within 
one minute. Negative test specimens were observed for 12 hours stored in a 
refrigerator. Though the intensity and velocity of color change varied with 
patients, those who tested positive developed a faint pink color change 
around the biopsy specimen immediately. The whole solution changed to 
pink color immediately in some whereas in others a faint pink color 
developed over a period of time. Bacterial load is said to be the factor 
affecting velocity and intensity of color change. Solutions without H.pylori 
remained yellow throughout. 
MERITS AND DEMERITS 
Various studies have compared the diagnostic accuracy of the RUT 
with all other diagnostic modalities. The test has been shown to have a 
sensitivity and specificity of 90% and 100% respectively. The test does not 
give false positive results unlike the conventional urease test in which 
contaminants like Proteus and Pseudomonas may give a positive result with 
prolonged incubation. The rapidity of the test is said to be due to the urea in 
water solution which is unbuffered like the Christenson’s urea broth. The 
test solution is very inexpensive and easy to prepare. The endoscopist 
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detects the infection even before the instrument is withdrawn. Treatment can 
be instituted at once and the outpatient reviews can be reduced. 
The main disadvantage is that the procedure is invasive requiring 
endoscopy and biopsy. Though mostly colonization of bacteria in the gastric 
mucosa is concentrated at the antrum, the distribution may be patchy and 
biopsy from multiple sites is said to further increase the sensitivity of the 
test. This procedure cannot be used for screening a general population where 
a serum based test like ELISA is more practical.  
Biopsy specimens from the body, fundus and antrum were analyzed 
for histopathological changes after staining with routine hematoxylin and 
eosin. 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002). Using 
this software, frequencies, percentages, means, standard deviations, chi 
square and 'p' values were calculated. Kruskul Wallis chi-square test was 
used to test the significance of difference between quantitative variables and 
Yate's test for qualitative variables. A 'p' value less than 0.05 is taken to 
denote significant relationship. 
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RESULTS AND ANALYSIS OF OBSERVED DATA 
EPIDEMIOLOGY 
Majority of the patients were from in and around Madurai. The age of the 
patients ranged from 18 to 82 years. Patients were nearly equally distributed 
in all age groups. Out of 224 patients included in the study, 21 (9.3%) were 
from the lower socioeconomic class, 85 (37.9%) from the upper lower class, 
91 (40.6%) from lower middle class and 27 (12%) from the upper middle 
class. The lower and upper lower classes were combined together as lower 
socioeconomic status (47.4%) and the lower middle and upper middle 
classes were combined together as middle socioeconomic status (52.6%).    
The mean age of the study population was 44.7+14.6 years. The age 
distribution of patients is shown in table 8. 
TABLE 6:  AGE DISTRIBUTION OF PATIENTS 
Age group(in 
years) 
18-29 
 
30-39 
 
40-49 
 
50-59 
 
>60 
 
MSES 19 30 21 16 20 
LSES 19 26 22 23 28 
TOTAL 38 56 43 39 48 
% 17 25 19.6 17 21.4 
Mean 44.7 years 
Standard deviation 14. 6 years 
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Among the 224 patients, 135 were male patients (60.3%) and 89 were 
female (39.7%). Out of the 135 male patients, 29 were chronic smokers 
(21%). 
SYMPTOMATOLOGY 
The most common complaint for which the patients sought medical 
help was upper abdominal pain and discomfort (90%) followed by post 
prandial fullness (78%). The duration of symptoms ranged between three 
months to six years. Out of the 224 patients, 102 patients (45.5%) presented 
within 3-6 months of onset of symptoms. The mean duration of symptoms 
was 15.3+14.7months.  About 50% of patients gave a history of multiple 
dyspeptic symptoms which implies that none of the symptoms are 
pathognomonic for a particular condition. No particular symptom was 
specifically associated with H.pylori positivity. 
TABLE 7:  DURATION OF SYMPTOMS 
Cases  
Duration of symptoms  
( in months) No. % 
Up to 6 102 45.5 
7 – 12 49 21.9 
13 – 24 36 16.1 
> 24 37 16.5 
Mean 
S.D. 
15.3 
14.7 
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Forty two` patients (18%) had one or more alarm symptoms already 
mentioned which was more prevalent in patients above 50 years age group. 
13 out of 48 patients (27.1%) in the >60 yrs age group had alarm symptoms. 
TABLE 8  
ALARM SYMPTOMS AND AGE 
Alarm Symptoms 
Present 
 
Absent 
 
Age (in years) 
No. % No. % 
Less than 30 (38) 5 13.2 33 86.8 
30-39 (56) 3 5.4 53 94.6 
40-49 (44) 11 25 33 75 
50-59 (38) 10 26.3 28 73.7 
60 & above (48) 13 27.1 35 72.9 
Mean 
S.D. 
50.14 
14.59 
43.49 
14.38 
‘p’ 0.0095 
Significant 
 
The value obtained was statistically significant (p=0.0095) 
implying that alarm symptoms were more with increasing age. 
There was no correlation between the alarm symptoms and gender, 
duration of disease or socioeconomic status. 
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Out of the 29 smokers, 10 (34.5%) had one or more alarm symptoms 
whereas alarm symptoms were absent in 84% of non smokers. 
TABLE 9 
ALARM SYMPTOMS VERSUS SMOKING STATUS 
Alarm Symptoms 
Present 
 
Absent 
 
Smoking among males 
(135) 
No. % No. % 
Yes (29) 10 34.5 19 69.5 
No (106) 17 16 89 84 
‘p’ 0.0284 
Significant 
 
There was a direct correlation between smoking and alarm 
symptoms (p=0.0284).  
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Endoscopic findings were analyzed and tabulated in order as shown in 
table 12. Duodenal ulcer was found in 17 (7.5%) patients, tumor/mass lesion 
in 9 (4.8%), non specific inflammation in the form of gastritis, duodenitis, 
esophagitis in 13 (5.8%), and normal study in 173 (77.2%) and other non 
specific findings in eight (3.5%) patients. 
TABLE 10  
ENDOSCOPIC FINDINGS 
 Ulcer Tumor Gastritis Normal  others 
MSES 3 7 13 90 5 
LSES 14 2 4 83 3 
TOTAL 17 9 13 173 8 
% 7.5 4 5.8 77.2 3.5 
 
Prevalence of ulcer was more in the lower socioeconomic status (14 
out of 17) and prevalence of tumor more in middle socioeconomic group 
(seven out of nine) but the values were not statistically significant. 
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Correlation between alarm symptoms and endoscopic findings was 
done using 50 years as the cut off age, since gastric malignancy is 
considered a rare diagnosis in the <50 age group. 
It was found that in the <50 years group, 13 out of 19 patients (68.4%) 
who had alarm symptoms had significant endoscopic lesions whereas 103 
out of 119 patients (86.6%) who did not have alarm symptoms had no 
lesions on endoscopy. Two patients had gastric carcinoma and both patients 
had alarm symptoms.  
On the other hand, in the >50 years group, 14 out of 23 patients 
(60.9%) who had alarm symptoms had serious lesions on endoscopy 
including gastric malignancy. Fifty five out of 63 patients (87.3%) without 
alarm symptoms had no endoscopic findings. 
This suggests that alarm symptoms may have good negative 
predictive value in both age groups.  
The results are summarized in table no 11. 
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TABLE 11: AGE, ALARM SYMPTOMS AND ENDOSCOPIC 
CORRELATION 
The value was statistically significant for both the age groups 
(p=0.0001) implying that alarm symptoms correlated well with 
significant endoscopic findings. Patients less than 50 years without 
alarm symptoms did not have any significant lesions whereas 
patients>50 years with alarm symptoms had a higher incidence of 
serious lesions. Thus alarm symptoms can be used to predict serious 
lesions.  
Endoscopic findings 
 
Present 
 
Absent 
 
Alarm Symptoms 
No. % No. % 
Less than 50 years (138) 
Present(19) 
 
13 
 
68.4 
 
6 
 
31.6 
Absent (119) 16 13.4 103 86.6 
‘p’ 0.0001 
significant 
More than 50 years (86) 
Present (23) 
 
14 
 
 
60.9 
 
9 
 
39.1 
 
Absent (63) 8 
 
12.7 55 87.3 
‘p’ 0.0001 
Significant 
Total (224) 
Present(42) 
 
27 
 
64.3 
 
15 
 
35.7 
Absent (182) 24 13.2 158 86.8 
‘p’ 0.0001 
Significant 
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Presence of H.pylori by the rapid urease test was analyzed amongst 
various endoscopic groups. Total number of patients who tested positive for 
H.pylori was 132 out of 224 (58.9%). The results are summarized in table 
12. 
  Amongst the various endoscopic groups, all patients with ulcer tested 
positive. None of the patients with tumors tested positive for the organism. 
102 out of 173 patients (59%) in the NUD group were positive for 
H.pylori. There was near equal prevalence of H.pylori in males (45.1%) and 
females (47.1%) in NUD. 
TABLE 12 
 H.PYLORI POSITIVITY IN ENDOSCOPIC LESIONS 
Ulcer Tumor Gastritis NUD others  
+ - + - + - + - + - 
MSES 3 0 0 7 4 9 45 45 2 3 
LSES 14 0 0 2 4 0 57 26 3 0 
TOTAL 17 0 0 9 8 9 102 71 5 3 
%  100 0 47 59 62.5 
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In the middle socioeconomic status, 54 out of 118 (45.8%) tested 
positive when compared with the lower socioeconomic status in which 78 
out of 108 (73.6%) were positive,  
TABLE 13 
 H.PYLORI AND SOCIOECONOMIC STATUS 
 
This implies that higher infection rates are seen in lower 
socioeconomic group. The difference was statistically significant 
(p=0.0001). 
 
 
 
 
H.Pylori 
 
Present 
 
Absent 
 
Socio Economic Status 
No. % No. % 
Low (106) 78 73.6 28 26.4 
Middle (118) 54 45.8 64 54.2 
‘p’ 0.0001 
Significant 
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Age wise positivity for H.pylori in NUD was analyzed. 29 out of total 
positives (36%) were in the age group of 30-39 years. The rest was equally 
distributed among the other age groups. Amongst the different age groups, 
25 patients with NUD above the age of 60 (70%) were positive and 29 
patients in the age group of 30-39 years (61.7%) tested positive for the 
organism indicating a bimodal age distribution.  
TABLE 14 
 AGE WISE POSITIVITY FOR H.PYLORI IN NUD 
18-29y 30-39y 40-49y 50-59y >60y  
Total + Total + Total + Total + Total + 
MSES 12 8 24 19 17 11 12 8 18 11 
LSES 18 5 23 10 16 8 16 6 18 14 
Total 30 13 47 29 33 19 28 14 36 25 
% 43..3 61.7 57.7 50 70
 
62% of patients with alarm symptoms had positivity for H.pylori in 
NUD. Most of them (85%) had ulcer like dyspepsia and the rest had 
dysmotility like dyspepsia but association was not statistically significant. 
 
 
 41
Out of 29 smokers, 24 (82.8%) tested positive for H.pylori.  
 
TABLE 15 
 H.PYLORI IN SMOKERS 
H.Pylori 
 
Present 
 
Absent 
 
Smoking among males 
(135) 
No. % No. % 
Yes (29) 24 82.8 5 17.2 
No (106) 59 55.7 47 44.3 
‘p’ 0.012 
Significant 
 
The association between the two variables was statistically 
significant (p=0.012), implying higher infection rates amongst smokers. 
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Histopathological findings of the biopsied specimen from three major 
sites were analyzed in relation to positivity of H.pylori in NUD patients. The 
findings are summarized in table 16. 
TABLE 16 
HISTOPATHOLOGICAL FINDINGS IN NUD 
 N AG BG FG PG LF IM 
RUT + - + - + - + - + - + - + - 
MSES 4 36 10 5 2 1 5 1 30 12 26 6 3 0 
LSES 20 16 24 2 3 1 10 4 16 3 16 1 1 0 
24 52 34 7 5 2 15 5 46 15 42 7 4 0 Total 
76 41 7 20 61 49 4 
% 33.9 18.3 3.1 8.92 27 21.87 1.7 
 
N – Normal study 
AG – Antral gastritis 
BG – Gastritis of the body of stomach 
PG – Pan gastritis 
FG – Fundal gastritis 
LF – Lymphoid follicles 
IM – Intestinal metaplasia 
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The following observations were made in relation to the 
histopathology of the mucosa in NUD- 
1. Out of 173 patients with NUD, 73 patients (33.9%) had no mucosal 
lesions and the rest 100 patients (66%) had mucosal lesions. Of the 100 
patients with lesions, 61 patients had pan gastritis. 
2. Thirty out of 118 patients of the middle socioeconomic status with RUT 
positivity had pan gastritis (38%). In the same socioeconomic group, a total 
of 32 patients had formation of intramucosal lymphoid follicles, compared to 
17 in the lower socioeconomic status. 
3. Isolated antral gastritis was more in lower socioeconomic status (n=24) 
than the middle socio economic status (n=10).  
4. Isolated fundal gastritis was present in a larger number in lower 
socioeconomic status both in RUT positive (n=10) and RUT negative 
patients (n=4).  
5.  Four patients had antral gastritis with intestinal metaplasia and all four 
were positive for H.pylori, out of which two patients were in the age group 
<50 years. 
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6. The presence of lymphoid follicles correlated well with longer duration of 
disease, as it was seen that 17 out of 37 patients (45.9%) with long duration 
of symptoms (lasting >24 months) had presence of lymphoid aggregates in 
mucosa. The value was statistically significant (p=0.0001).   
TABLE 17 
 DURATION OF SYMPTOMS VERSUS PRESENCE OF LYMPHOID 
FOLLICLES 
Lymphoid Follicles 
 
Present 
 
Absent 
 
Duration of symptoms 
(in months) 
No. % No. % 
Up to 6 (102) 10 9.8 92 90.2 
7 – 12 (49) 13 26.5 36 73.5 
13 – 24 (36) 9 25 27 75 
> 24 (37) 17 45.9 20 54.1 
Mean 
S.D. 
23.27 
16.96 
13.07 
13.18 
‘p’ 0.0001 
Significant 
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TABLE 18 
 SITE OF GASTRITIS AND LYMPHOID FOLLICLES 
Lymphoid Follicles 
 
Present 
 
Absent 
 
Site of Gastritis 
No. % No. % 
AG (53) 19 35.8 34 64.2 
BG (3) 1 33.3 2 66.7 
FG (20) 1 5 19 95 
PG (63) 28 44.4 35 55.6 
 
Lymphoid follicles were almost equally distributed at all sites in 
the stomach. 
 
 
 
 
 
 
 
. 
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Out of 42 patients who had one or more alarm symptoms, 36 patients 
(85.7%) had significant mucosal lesions.  
TABLE 19 
 ALARM SYMPTOMS VERSUS HISTOPATHOLOGY 
Histopathological findings 
 
Present 
 
Absent  
 
Alarm Symptoms 
No. % No. % 
Present (42) 36 85.7 6 14.3 
Absent (182) 111 61 71 39 
‘p’ 0.0042 
Significant 
 
There was good correlation between alarm symptoms and 
histopathological findings. The value was statistically significant 
(p=0.0042).  
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The relation between H.pylori positivity and histopathology of gastric 
mucosa in NUD was analyzed. Out of 100 patients with mucosal lesions in 
NUD, 83 of them (81.4%) tested positive for H.pylori.   
TABLE 20 
 CORRELATION BETWEEN HISTOPATHOLOGY AND H.PYLORI 
POSITIVITY IN NUD 
Histopathological findings  
 
Present Absent  
 
RUT findings among 
normal Endoscopy cases 
(173) No. % No. % 
Positive (102) 83 81.4 19 18.6 
Negative (71) 17 23.9 54 76.1 
‘p’ 0.0001 
Significant 
 
The correlation between the two variables was found to be 
statistically significant (p=0.0001). 
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Forty nine patients with NUD (21.9%) had lymphoid follicles in our 
study. Out of these, 42 patients tested positive for H.pylori.  
TABLE 21 
LYMPHOID FOLLICLES VERSUS H.PYLORI STATUS 
 
Significant correlation was found between the presence of 
lymphoid follicles and H.pylori positivity in NUD (p=0.0001).  
 
 
 
 
 
Lymphoid Follicles 
 
Present 
 
Absent 
 
RUT findings among 
NUD cases (173) 
No. % No. % 
Positive (102) 42 31.4 60 68.6 
Negative (71) 7 7 64 93 
‘p’ 0.0001 
Significant 
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DISCUSSION 
 Dyspepsia is a common symptom with an extensive differential 
diagnosis and a heterogeneous pathophysiology. Since dyspepsia affects 
large numbers of people across a broad spectrum of symptoms, it is not 
practical to perform endoscopy in all patients with dyspepsia. The 
appropriate role of endoscopy in the evaluation of dyspepsia is both a 
pragmatic concern for the gastroenterologist and an important determinant in 
healthcare costs.  This study on the evaluation of upper GI endoscopy in 
dyspepsia was mainly done to assess the usefulness of endoscopy in patients 
presenting with new onset dyspeptic symptoms and to study the relation 
between H.pylori and non ulcer dyspepsia.  
Most of the observations made in this study correlated well with 
world literature. Several studies done in the past have suggested that routine 
upper gastrointestinal endoscopy for a younger patient with dyspepsia is not 
indicated as the initial diagnostic procedure.8,9,13,35,36,37  The most common 
endoscopic finding in our study was non ulcer dyspepsia (77.2%). The 
incidence of gastric malignancy is generally low in patients below the age of 
50 and this has been observed in several studies in past. Similarly, in our 
study, the overall incidence of gastric malignancy was low and even lower in 
patients below the age of 50 years. Only two patients below the age of 50 
 50
years had malignancy and both these patients had significant alarm 
symptoms to indicate the seriousness of the lesion.  
The importance of alarm symptoms is evident from the fact that they 
correlated very well with the presence of serious endoscopic lesions 
(p=0.0001). They had good negative predictive value in patients < 50 years.  
This was in accordance with the previous studies done by Johannesen et al8 
and Mansi et al9 in which the authors found a good negative predictive value 
of alarm symptoms (97%). Conversely, a significant proportion of patients 
>50 years with serious endoscopic lesions had one or more alarm symptoms. 
Alarm symptoms can safely be used to decide which group of patients need 
endoscopy (p=0.0001). This is in concordance with the large study done by 
Williams et al in 1988 which suggested that endoscopy may not needed in 
patients under the age of 45 years.13  It is neither cost effective nor 
diagnostic. On the other hand, detailed evaluation of symptoms and physical 
signs can help to decide which groups of patients need endoscopic 
evaluation. 
The diagnostic workup for dyspepsia in the recent past has been 
dominated by initial testing for H.pylori and its eradication, bearing in mind 
the fact that it is strongly associated with most gastroduodenal disorders 
including non ulcer dyspepsia. This has been highlighted by three recent 
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major trials which have compared endoscopy with HP testing (Veldhuyzhen 
et al35, Zagari et al36, and Mahadeva et al37). All the three trials have proved 
that endoscopy is not a cost effective procedure as compared to HP test and 
treat. The yield from endoscopy for patients below 50 years was very low.  A 
non invasive approach to the diagnosis of H.pylori is preferred. 
There was similar correlation with regard to prevalence of H.pylori. 
There have been several studies published in India and the West which have 
tried to analyze the importance and prevalence of H.pylori in various gastric 
lesions. Our study reports a prevalence rate of 59% in non ulcer dyspepsia 
which compares well with world literature. The prevalence rates are 
summarized in the following table. 
Clinical condition World figures1 Our study 
Duodenal ulcer 95-98% 100% 
Gastritis 50-65% 47% 
Non ulcer dyspepsia 50-60% 59% 
Gastric carcinoma six fold increase 0% 
 
There was a higher prevalence of the infection in the lower 
socioeconomic status (p=0.0001) and this is consistent with the 
epidemiology of the infection. This was previously demonstrated in a 
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population study performed by Paul Moayeddi et al in the United Kingdom 
which found significant correlation between H.pylori and poor living 
conditions.38 There was no particular sex predilection in past studies and 
similar results were obtained in our study too.38 There was almost equal 
prevalence of infection in males (45.1%) and females (47.1%). No specific 
symptom correlated with the presence of H.pylori in our study and this fact 
has been well emphasized in the past also. 
The etiology of non ulcer dyspepsia remains elusive. Most researchers 
believe that there is a relation, although an imperfect one, between non-ulcer 
dyspepsia and infection with H.pylori. The pathophysiological mechanisms 
by which the infection may cause dyspepsia are unclear, but may include 
changes in acid secretion, abnormal motility, or altered visceral perception. 
The association of non ulcer dyspepsia with H. pylori infection has been 
widely reported in the recent past.24,38,39,40 However, the issue of whether this 
relation is causal or casual still remains debatable. 
 Several studies have assessed the epidemiological association 
between H. pylori infection and non ulcer dyspepsia. There was good 
correlation of our findings with the previous studies in India on non ulcer 
dyspepsia and its relation to H.pylori. These studies showed a peak age 
prevalence of between 30-39 years. A slight variation was observed in this 
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study in that there was a bimodal distribution of H.pylori (30-39 years, >60 
years). This could probably be explained by the fact that Helicobacter 
infection increases with age and also to increased longevity. The previous 
study done in Madurai by Thayumanavan et al reported a prevalence rate of 
around 50.3% in non ulcer dyspepsia.24  
 
There was a significant correlation between smoking and presence of 
H.pylori infection (p=0.012) in our study. Nearly 83% of smokers were 
infected. Previous studies have also indicated that smoking is a significant 
risk factor for H.pylori infection. A study done by Murray et al in Northern 
Ireland analyzed the relation of H.pylori to smoking and alcohol and showed 
that the prevalence of H.pylori was higher in smokers and ex smokers.41 
In our study, we studied the histopathology of the gastric mucosa in 
non ulcer dyspepsia to see if there were any significant lesions. Studies on 
  GILL ET AL39 
KHANNA
ET AL40 
 
THAYUMANAVAN 
ET AL24 
Our study 
Prevalence 46 % 74 % 
 
50.3% 59% 
Age group 20 - 40 ----- 
 
              30-40 Bimodal 30-39 
>60 yrs 
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the histology of non ulcer dyspepsia are lacking and there is very limited 
information available. There are no large scale studies in India.  The findings 
in our study correlated well with the previously done studies. Out of 173 
patients with non ulcer dyspepsia, 117 patients (68%) had significant 
mucosal lesions including lymphoid aggregates and intestinal metaplasia. 
One study done in Nigeria by Sylvester et al showed that a significant 
proportion of patients with non ulcer dyspepsia (70%) had gastric mucosal 
lesions.32 A similar study was done by Schade et al and also demonstrated 
the need for further evaluation of the mucosa in non ulcer dyspepsia.42 
 A significant proportion of patients with gastric lesions had evidence 
of H.pylori infection (p=0.0001). Among the patients who had mucosal 
lesions, 81.4% of patients were positive for H.pylori. This has been well 
emphasized in the study done by Sylvester et al.32 This indicates that 
H.pylori could be responsible for the dyspeptic symptoms and the mucosal 
lesions in the stomach.  
Lymphoid follicles in the gastric mucosa represent a common 
response to H. pylori infection. The range of this response varies from 27% 
to 100% in previous publications.32,43,44,45 Previous studies have concluded 
that the presence of lymphoid follicles in the gastric mucosa appears to be a 
strong predictor of H. pylori infection. The importance of lymphoid 
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transformation of the gastric mucosa has been well stressed in a 
retrospective study of gastric mucosal biopsies done by Mohammed Afzal et 
al in Saudi Arabia which found a significant correlation between lymphoid 
follicles and presence of H.pylori infection. In this study nearly 95% of 
patients with lymphoid follicles had evidence of H.pylori infection.45 
 They concluded that finding even a single lymphoid follicle in a 
gastric biopsy specimen is associated with a very high probability (>90%) of 
detecting H. pylori in the same or in another synchronous biopsy specimen 
obtained from that patient. 
There were similar observations made in our study. Forty nine 
patients with NUD in our study had lymphoid aggregates in the gastric 
mucosa out of which 42 (85.4%) were positive for H.pylori. There was a 
significant relation between the presence of lymphoid aggregates and 
H.pylori infection in our patients (p=0.0001) and there was also significant 
correlation between the duration of symptoms and presence of lymphoid 
aggregates (p=0.0001). More than 50% of the patients with lymphoid 
follicles had a long duration of symptoms. This probably reflects the 
chronicity and severity of the lesions despite the presence of normal 
endoscopy, placing these patients at risk of the indolent gastric MALT 
lymphoma.  
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Our study supports the conclusion derived from the study done by 
Mohammed et al.45 The conclusion derived from that study was that 
lymphoid follicles are absent in the normal stomach, therefore their 
appearance in the stomach with H. pylori associated gastritis, is an issue of 
considerable interest. The development of mucosa associated lymphoid 
tissue is a necessary first step in the development of primary MALT 
lymphoma in various organs such as lung, thyroid or stomach that are 
normally devoid of MALT . Therefore, association in the stomach mucosa 
suggests a causal relationship between H. pylori and the origin of gastric 
MALT lymphoma. The present study supports other reports that H pylori 
infection may be directly related to the development of gastric MALT 
lymphoma. This provides the necessary background where other as yet 
unidentified factors may act leading to the development of lymphoma in a 
small proportion of cases. Also it supports the concept that eradication of H. 
pylori results in prevention or regression of previously developed 
MALTOMA of the stomach which has been emphasized in the past.1,2 
Further controlled studies and therapeutic trials would help further clarify 
this relationship. 
In a retrospective study done by Ghoshal et al in Indian patients with 
gastric lymphomas, it was found that these patients had repeatedly normal 
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endoscopies and the diagnosis was achieved only on gastrectomy.50 
Furthermore, there was a very strong association between gastric 
lymphomas and H.pylori. Our study has shown significant gastric lymphoid 
aggregates despite normal endoscopy. Lymphomas evade diagnosis most of 
the times requiring high degrees of suspicion. They must be identified early 
because they are completely curable in early stages. It may be worth 
subjecting these patients to eradication therapy to prevent malignancy in 
future.46, 47, 48, 49 Jakkimeinen et al showed that H.pylori was associated with 
a significant number of cases of non ulcer dyspepsia and eradication 
produced reasonable symptomatic benefit in these patients.48 There was 
similar observation made by Paul Moayyedi et al in a meta analysis.46 There 
are no large scale follow up studies to study the status of the mucosa on 
follow up and the very few early studies have suggested further evaluation 
of the mucosal status.43, 44, 45   
The association between H.pylori and gastric carcinoma was 
negligible in our study consistent with past Indian studies. None of the 
patients with malignancy tested positive for H.pylori.  It has been referred to 
as the Indian enigma. The study done by Ghoshal et al concluded that 
H.pylori prevalence was not significantly different amongst patients with 
carcinoma and controls. Indian patients were also found to have less 
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incidence of gastric cancer despite the high prevalence of H.pylori infection, 
thus raising doubts about the direct association of H.pylori infection with 
gastric adenocarcinoma. The reason quoted is the presence of some genetic, 
dietary or environmental factors which have a protective effect against the 
development of malignancy. This has not been proved to date and needs 
further evaluation.50 
It may be worth performing a triple site mucosal biopsy for early 
identification of lymphoid infiltration into the stomach.  Patients with gastric 
lymphoid aggregates may have to be subjected to immunological studies to 
detect the presence of low grade MALT lymphomas. Further follow up of 
these patients is needed to find the response rates.  
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SUMMARY 
The study “Evaluation of upper gastrointestinal endoscopy in with 
special reference to Helicobacter pylori in non ulcer dyspepsia” was a cross 
sectional study of 224 patients admitted with new onset dyspepsia in 
Government Rajaji Hospital, Madurai. 
Patients who satisfied the inclusion criteria were interviewed for 
dyspeptic symptoms and alarm symptoms. They underwent investigations 
like ultrasonography, upper gastrointestinal endoscopy and tissue urease test 
for H.pylori with mucosal biopsy. The correlation between alarm symptoms, 
endoscopic findings and histopathological findings was analyzed. Patients 
without alarm symptoms did not have serious lesions on endoscopy or 
histopathology. There was high prevalence of H.pylori in lower 
socioeconomic population and smokers. Significant mucosal inflammatory 
lesions were present on histopathological examination in patients with 
normal endoscopy but positive for H.pylori. 
 This study highlights the fact that endoscopy is not warranted in 
patients <50 years with new onset dyspepsia and without alarm symptoms. 
Testing for H.pylori is needed in all patients with dyspepsia and 
histopathology of mucosa may be required in patients who test positive for 
H.pylori for early detection of lymphoid transformation in the stomach. 
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CONCLUSIONS 
1. There was significant correlation between alarm symptoms and gastric 
lesions in dyspepsia; hence endoscopy is recommended for these patients.  
2. In patients aged <50 years without alarm symptoms, endoscopy did not 
reveal any lesions. Hence endoscopy may not be needed routinely in these 
patients; they can be managed with the “treat first, test later” approach. 
3. H.pylori was prevalent in 60% of patients with NUD and was comparable 
with world literature. 
4.  H.pylori prevalence was highest in 4th to 7th decade.  
5. H.pylori prevalence was significantly higher in the lower socioeconomic 
status. 
6.  Smoking is a significant risk factor for H.pylori. 
7. H.pylori positivity was associated with significant mucosal lesions 
including lymphoid follicles and intestinal metaplasia despite normal 
endoscopy; hence routine biopsy of the mucosa is needed. 
8. The initial concept of ignoring H.pylori in non ulcer dyspepsia may have 
to be redefined since many patients in our study had significant mucosal 
lesions. 
9. Further immunological studies may be needed to evaluate patients with 
lymphoid follicles to detect the presence of low grade MALToma. 
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PROFORMA 
S.NO. 
NAME       AGE:  SEX: 
ADDRESS:       UNIT: WARD: 
        OP/IP NO: 
Occupation:  
Educational status: 
Monthly income:  
Socioeconomic status score:  
SOCIOECONOMIC STATUS:  
      COMPLAINTS      DURATION 
1. Upper abdominal pain  
2. Abdominal discomfort 
3. Bloating sensation 
4. Early satiety 
5. Post prandial fullness 
   ALARM SYMPTOMS                                                    DURATION 
1. Dysphagia 
2. Upper GI bleed (hematemesis/melena) 
3. Persistent vomiting 
4. Sensation of an abdominal mass 
5. Jaundice 
6. Loss of weight 
7. Loss of appetite 
 
 
PAST HISTORY: 
Systemic illness: 
Drug intake: (antibiotics/ PPI/metronidazole/NSAIDs/others) 
Prior endoscopy: Y/N 
PERSONAL HISTORY: 
Alcohol intake: Y/N     Smoking: Y/N 
Betel chewing: Y/N 
EXAMINATION: 
Nutritional status:     oral hygiene: good/poor 
Anemia: Y/N     jaundice: Y/N 
Lymphadenopathy: Y/N 
Abdomen:  epigastric tenderness: Y/N 
         Abdominal mass: Y/N 
INVESTIGATIONS: 
1. Blood urea (mg/dl): 
2. Serum creatinine (mg/dl): 
3. Hemoglobin (grams/dl): 
4. ESR (mm in 1 hour): 
5. Ultrasonography of abdomen: 
 
6. Upper GI endoscopy: 
 
7. Rapid urease test: +/- 
8. Biopsy findings: 
 
 
 
 
FIGURE 1: DISCOVERERS OF H.PYLORI: BARRY 
MARSHALL AND WARREN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: RELATION OF H.PYLORI TO GASTRIC MUCOSA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3: GASTRIC MUCOSA: HISTOPATHOLOGY AND 
H.PYLORI 
 
 
 
 
FIGURE 4: GASTRIC INTRAMUCOSAL LYMPHOID 
AGGREGATES 
 
 
FIGURE 5: THE ULTRA RAPID UREASE REACTION 
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FIGURE 6: AGE DISTRIBUTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7: SOCIOECONOMIC STATUS 
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FIGURE 8: ENDOSCOPIC FINDINGS 
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FIGURE 9: ALARM SYMPTOMS AND ENDOSCOPIC 
CORRELATION 
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FIGURE 10: H.PYLORI AND SOCIOECONOMIC STATUS 
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FIGURE 11: H.PYLORI AND SMOKING STATUS 
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FIGURE 12: HISTOPATHOLOGICAL FINDINGS IN RUT 
POSITIVE NUD PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 13: HISTOPATHOLOGICAL FINDINGS IN RUT 
NEGATIVE NUD PATIENTS 
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FIGURE 14: DURATION OF SYMPTOMS VERSUS 
LYMPHOID FOLLICLES 
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FIGURE 15: H.PYLORI VERSUS HISTOPATHOLOGICAL 
LESIONS IN NUD PATIENTS 
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FIGURE 16: H.PYLORI VERSUS LYMPHOID FOLLICLES  
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81 60 F 8 UL 24m N N n 9.8 40 1.2 28 n n + PGLF
82 46 M 9 UL 36m N N et 10.2 28 0.9 20 n ER + PGLF
83 27 M 10 UL 6m N Y et 11 30 0.9 10 n DB + AGLF
84 32 M 9 UL 36m N N n 12.2 18 0.9 10 n n + n
85 33 M 10 UL 5m N N et 12 24 0.9 24 n n + PG
86 65 M 9 UL 6m N N n 14 23 1 10 n n - n
87 73 F 4 L 24m N N et 9 30 1.2 34 n n + PGLF
88 60 M 4 L 4m Y Y et 8.8 43 0.9 30 n n + n
89 37 M 4 L 3m N Y et 12.9 34 0.9 12 n n + n
90 24 M 9 UL 6m yes N et 13 23 1 10 n DU + AGLF
91 45 F 6 UL 8m N N n 12 19 0.9 15 n n + PGLF
92 35 F 6 UL 12m N N n 13.2 18 1 20 n n + FGAG
93 50 F 7 UL 24m N N n 14 23 0.7 24 FL n + PG
94 42 M 10 UL 36m N N n 12 34 0.9 28 n n - n
95 45 M 9 UL 3m N Y n 12.7 24 1 12 n n - AGLF
96 37 F 8 UL 4m N N n 13.6 23 1 10 FL n + PGLF
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97 52 F 6 UL 24m Y N n 8.6 42 1.6 105 n n - n
98 47 M 7 UL 10m N N n 12 30 1.2 10 n n - n
99 32 M 10 UL 6m N Y n 13.5 38 0.9 14 n n + BGAG
100 70 M 9 UL 6m N N n 12 23 0.9 34 n n - AG
101 45 F 8 UL 12m N N n 12.5 34 0.7 20 n n + n
102 64 M 9 UL 4m N N n 10 25 1 36 n n - PG
103 62 F 7 UL 36m N N n 10.8 23 1.2 26 n n + AG
104 44 M 6 UL 6m N N n 13 24 1 20 n HG + AG
105 38 M 10 UL 36m N N n 12 26 0.8 34 n n - n
106 45 M 9 UL 48m Y N n 10 34 1 48 n ND + PGLF
 MIDDLE SOCIOECONOMIC STATUS 
107 29 F 22 UM 6m N N n 12 19 0.8 20 n n - PG
108 60 M 12 LM 12m N N n 13 28 1 26 n n + n
109 41 F 12 LM 24m N N n 12 28 1.2 20 FL n + PG
110 52 F 14 LM 24m N N et 11.8 18 0.9 22 FL n + n
111 20 F 11 LM 3m N N n 10.8 18 0.8 18 n n - n
112 35 F 12 LM 24m N N n 11 18 0.8 18 FL  n + n
113 31 M 15 LM 36m N N et 13 28 1.1 18 n n - n
114 29 F 11 UM 3m N N et 12.8 18 0.6 20 n n - n
115 56 M 12 LM 6m N N n 13.8 38 1.2 12 n n - PG
116 65 F 13 LM 3m N N n 10.8 36 1.2 20 n n - n
117 67 M 14 LM 12m N Y et 9.6 40 1 40 n n + PGLF
118 62 M 11 LM 36m N N n 13 38 1.2 12 n n + PG
119 25 F 15 LM 6m N N n 12.2 24 1 10 n n + AG
120 19 F 19 UM 3m N N n 13 20 0.6 12 n n - n
121 27 F 12 LM 4m N N n 12.3 14 0.7 16 n n - n
122 76 M 11 LM 6m N N n 10 28 1 50 n n + PGIM
123 45 F 15 LM 36m N N n 9.8 30 1 20 n n + PGLF
124 45 M 14 LM 6m N N n 14 38 1.2 18 n n - n
125 67 F 23 UM 8m N N n 9 28 1 40 n n + PG
126 70 M 23 UM 12m N N n 8.8 40 1 60 n n + IM
127 32 M 15 LM 24m N N n 12.8 34 0.9 14 n n + PGLF
128 60 F 12 LM 5m N N n 11 24 1.3 12 n n + AG
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129 47 M 13 LM 12m Y Y et 12.3 20 0.9 14 n n + PGLF
130 26 M 14 LM 8m N N n 13 34 0.9 34 n n - n
131 45 M 23 UM 7m N N n 12 23 0.8 20 n n + PGLF
132 63 M 13 LM 6m N N n 10 34 1 24 n n + PG
133 57 M 14 LM 7m N N n 12 40 1 30 n n + AG
134 27 F 12 LM 8m N N n 13.2 20 0.7 24 n n + PGLF
135 67 M 11 LM 6m N N et 13 30 1 12 n n - n
136 22 F 11 LM 24m N N n 11 20 0.7 14 n n + PGLF
137 38 F 23 UM 24m N N n 12.8 20 0.9 20 n n + PGIM
138 68 M 12 LM 24m Y N n 8.2 56 3.2 20 n AG + PG
139 60 F 12 LM 3m N N n 12.8 30 1.1 20 n E - n
140 47 M 13 LM 36m N N n 13.4 28 1 30 n n + PG
141 82 M 14 LM 12m Y N n 12 38 1.3 16 n ER - PG
142 62 M 11 LM 6m Y Y et 7.3 50 1.8 50 n AG + PG
143 55 M 11 LM 48m Y N et 9 28 1 48 n ADU + AG
144 70 F 23 UM 6m N N et 12.2 30 1.1 20 n n - n
145 52 M 13 LM 12m N N n 13.2 30 0.9 10 n n - n
146 54 M 11 LM 24m N N n 14 30 0.9 10 n n - n
147 52 M 12 LM 6m N N n 13.9 30 1.2 14 n n - n
148 49 M 15 LM 3m N N n 13.6 40 1.2 26 n E - AG
149 52 M 23 UM 48m N N n 14 32 0.9 10 n n - BGLF
150 33 F 14 LM 3m N N n 12.2 36 0.9 12 n n - n
151 29 M 12 LM 3m N N n 13.6 16 0.9 10 n n - n
152 72 F 13 LM 4m Y N et 6.2 42 1 68 GOO AGR - PDAC
153 33 M 11 LM 24m N N n 13 35 1 12 n n + AGLF
154 56 F 11 LM 6m N N n 13.8 28 0.9 20 FL n - n
155 27 F 13 LM 24m N N n 12 19 0.8 20 n n - n
156 49 M 15 LM 6m N N n 13 36 0.9 22 n SD - n
157 56 F 15 LM 24m N N n 12 26 0.9 20 n n - n
158 32 F 13 LM 6m N N n 12.8 18 0.8 22 FL n - n
159 31 M 21 UM 6m N N n 13 30 0.8 10 FL n - n
160 39 M 13 LM 24m N N n 12.6 18 0.8 22 n n - AGLF
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161 48 F 12 LM 3m N N n 12 19 0.6 20 FL n - n
162 34 M 11 LM 24m N N n 14 20 0.8 24 n G - PG
163 29 M 21 UM 12m N N n 12.9 20 0.8 10 n n - n
164 43 M 14 LM 12m N N n 13 30 0.7 14 n n - AGLF
165 35 F 15 LM 6m N N et 13 20 0.9 20 FL n + AGLF
166 63 F 15 LM 4m Y N et 6.2 40 0.8 92 n OGJG - PDAC
167 30 M 14 LM 36m N N n 12.2 19 0.8 26 n ND - AGLF
168 40 F 18 UM 6m Y N et 9 20 0.8 90 n OGJG - PDAC
169 55 F 12 LM 36m N N et 12.6 20 0.8 32 FL n + PGLF
170 40 F 12 LM 48m N N et 13 20 0.6 20 n n + PGLF
171 26 M 13 LM 36m Y N et 13.2 19 0.7 40 n n + AGLF
172 46 M 15 LM 3m Y N et 8.2 38 1.4 78 n OGJG - PDAC
173 30 M 19 UM 5m N N n 14 20 0.9 10 n n - n
174 52 F 11 LM 8m Y N et 7 39 1 56 n OGJG - PDAC
175 36 M 11 LM 5m N N n 13.5 28 0.9 10 n n - n
176 40 M 11 LM 7m N N n 12 20 0.9 24 n n + AG
177 24 M 13 LM 36m N N n 14 23 1 14 n n + AGLF
178 36 M 14 LM 3m N N et 12.2 22 0.8 22 n n + FGLF
179 52 F 14 LM 5m Y N et 8.7 34 1 68 n FGR - PDAC
180 52 F 21 UM 12m N N n 13 23 0.8 24 n n - n
181 67 M 12 LM 6m Y N n 7.2 122 4.6 110 n n + PGLF
182 70 M 23 UM 60m N N n 11.8 30 0.8 10 n n + n
183 65 M 15 LM 36m N N et 10 23 1 24 n ER + PGLF
184 50 M 12 LM 5m N Y et 14 23 1 10 n ER + n
185 30 M 21 UM 24m N N et 13.2 23 0.8 12 n n + PG
186 35 M 13 LM 6m N N n 12 30 0.9 14 n n + PG
187 53 M 13 LM 12m N N n 14.2 38 0.9 10 n n - n
188 55 F 15 LM 12m Y N et 9 23 0.8 24 n n + PGLF
189 64 F 21 UM 24m N N n 12.3 24 1.2 40 n n + FGBG
190 60 M 13 LM 4m Y N n 7 40 1.2 60 n FGR - PDAC
191 62 F 12 LM 6m N N n 8.2 50 2.5 130 n n + PGLF
192 36 M 11 LM 12m N N n 14 23 1 34 n n - n
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193 39 M 11 LM 24m N N n 13.6 38 1.3 20 n n - AGLF
194 51 M 23 UM 36m N N n 13 24 0.9 20 n n + FGBG
195 40 M 14 LM 6m Y N n 14 24 1 12 n SD + FGAG
196 40 F 15 LM 6m N N n 12.3 20 0.7 10 n n - n
197 65 F 12 LM 24m N N n 10 40 1 20 n E - AG
198 42 F 13 LM 24m N N et 12.8 34 1.2 14 n n - PG
199 38 F 22 UM 24m N N n 11 34 0.7 20 n n + FG
200 65 M 12 LM 36m N N et 12 45 1.2 30 n n + PGLF
201 36 M 12 LM 36m N N n 13 20 0.9 10 n n + PGLF
202 23 F 21 UM 12m Y N n 12.6 23 1 18 n DUO + AGLF
203 67 M 14 LM 12m N N n 13 40 1.2 34 n n - n
204 32 M 19 UM 6m N N n 14 23 1.2 10 n n - n
205 29 M 11 LM 48m N N n 13.7 19 0.8 18 n n + PGLF
206 75 M 14 LM 36m Y N n 10 23 1.3 56 n E - FG
207 37 M 23 UM 48m N N n 12.3 20 0.9 20 n n + AGLF
208 55 M 15 LM 6m Y Y n 10 34 1.4 24 n E - FG
209 38 M 14 LM 5m N N n 14 23 1.4 10 n n - n
210 28 M 11 LM 6m N N n 13.8 23 0.6 10 n n - PG
211 35 M 21 UM 12m Y N n 12 24 1.3 24 n SD + PGLF
212 40 F 12 LM 3m N N n 11.8 20 1.2 34 n n + PG
213 32 F 13 LM 6m N N n 12 20 0.9 18 n n - n
214 58 M 15 LM 24m N N n 11.6 40 1.4 20 n n + PGLF
215 42 F 22 UM 36m Y N n 6.2 34 1 60 n HG - PDAC
216 58 M 12 LM 8m N N n 11.2 45 1 36 n n - n
217 56 F 12 LM 9m N N n 12 36 1 40 n ER - PG
218 55 M 11 LM 12m N N n 13 40 1 28 n E - PG
219 27 M 15 LM 24m N N et 13.9 24 0.7 10 n n - n
220 43 M 20 UM 6m N N et 14 26 1.2 24 n n - n
221 48 M 13 LM 12m Y N et 10 24 1.2 30 n ADU + AGLF
222 64 F 12 LM 4m N N et 12.2 40 1.4 28 n n + AG
223 43 M 18 UM 6m N N et 14 26 1.3 40 n n - PG
224 23 F 20 UM 5m N N n 12 24 0.6 10 n n - n
 
 
 
 
 
 
KEY TO MASTER CHART 
 
+ Positive 
- Negative 
ADU - Acute Duodenal Ulcer 
AG - Antral Gastritis 
AGR - Antral Growth 
BG - Gastritis of Body 
CDU - Chronic Duodenal Ulcer 
DB - Deformed Bulb 
DUO - Duodenal Ulcer with Obstruction 
E - Esophagitis 
ER - Erosive Gastritis 
ESR- Erythrocyte Sedimentation Rate 
ET – Epigastric Tenderness 
F - Female  
 
FG - Fundal Gastritis 
FGR - Fundal Growth 
FL - Fatty Liver 
GOO - Gastric Outlet Obstruction 
HG - Hypertrophic Gastritis 
IM - Intestinal Metaplasia 
L – Lower Socioeconomic Class 
LF - Lymphoid Follicles 
LM – Lower Middle Socioeconomic Class      
M - Male   
m – Months 
n – Normal 
N – No 
ND - Nodular Duodenum 
OGD - Endoscopy  
OGJG - Oesophagogastric Junction Growth        
PDAC - Poorly Differentiated Adenocarcinoma 
PG - Pan Gastritis 
RUT - Rapid Urease Test 
SD - Scarred Duodenum  
Y – Yes 
UL – Upper Lower Socioeconomic Class 
UM – Upper Middle Socioeconomic Class      
USG - Ultrasonogram 
 
